Related references
Note: Only part of the references are listed.Design, synthesis and biological evaluation of 2-amino-4-(1,2,4-triazol)pyridine derivatives as potent EGFR inhibitors to overcome TKI-resistance
Haikui Yang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2020)
Discovery of thiazolidin-4-one urea analogues as novel multikinase inhibitors that potently inhibit FLT3 and VEGFR2
Baohui Qi et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2019)
Discovery of N1-(4-((7-(3-(4-ethylpiperazin-1-yl)propoxy-)6-methoxyquinolin-4-yl)oxy)-3,5-difluorophenyl)-N3-(2-(2,6-difluorophenyl)-4-oxothiazolidin-3-yl)urea as a multi-tyrosine kinase inhibitor for drug-sensitive and drug-resistant cancers treatment
Baohui Qi et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
Type IIA - Type IIB protein tyrosine kinase inhibitors hybridization as an efficient approach for potent multikinase inhibitor development: Design, synthesis, anti-proliferative activity, multikinase inhibitory activity and molecular modeling of novel indolinone-based ureides and amides
Wagdy M. Eldehna et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
Discovery and optimization of a series of 3-substituted indazole derivatives as multi-target kinase inhibitors for the treatment of lung squamous cell carcinoma
Qi Wang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
The p53 stabilizing agent CP-31398 and multi-kinase inhibitors. Designing, synthesizing and screening of styrylquinazoline series
Jacek Mularski et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
CRISPR-Cas9 for cancer therapy: Opportunities and challenges
Minjiang Chen et al.
CANCER LETTERS (2019)
Design of a Cyclin G Associated Kinase (GAK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Set to Interrogate the Relationship of EGFR and GAK in Chordoma
Christopher R. M. Asquith et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Targeting an EGFR Water Network with 4-Anilinoquin(az)oline Inhibitors for Chordoma
Christopher R. M. Asquith et al.
CHEMMEDCHEM (2019)
Discovery of a Furanopyrimidine-Based Epidermal Growth Factor Receptor Inhibitor (DBPR112) as a Clinical Candidate for the Treatment of Non-Small Cell Lung Cancer
Shu-Yu Lin et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Design, synthesis and biological evaluation of novel 4-anilinoquinazoline derivatives as hypoxia-selective EGFR and VEGFR-2 dual inhibitors
Huiqiang Wei et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
Discovery of Potent and Orally Effective Dual Janus Kinase 2/FLT3 Inhibitors for the Treatment of Acute Myelogenous Leukemia and Myeloproliferative Neoplasms
Tao Yang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Discovery of anilino-furo[2,3-d]pyrimidine derivatives as dual inhibitors of EGFR/HER2 tyrosine kinase and their anticancer activity
Monia Hossam et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Identification of novel N1-(2-aryl-1, 3-thiazolidin-4-one)-N3-aryl ureas showing potent multi-tyrosine kinase inhibitory activities
Baohui Qi et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Design, synthesis and biological evaluation of a series of novel 2-benzamide-4-(6-oxy-N-methyl-l-naphthamide)-pyridine derivatives as potent fibroblast growth factor receptor (FGFR) inhibitors
Manman Wei et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Dual or multi-targeting inhibitors: The next generation anticancer agents
Nulgumnalli Manjunathaiah Raghavendra et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Identification of highly potent BTK and JAK3 dual inhibitors with improved activity for the treatment of B-cell lymphoma
Yang Ge et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Design, synthesis and structure-activity relationship of diaryl-ureas with novel isoxazol[3,4-b]pyridine-3-amino-structure as multi-target inhibitors against receptor tyrosine kinase
Zhi-Hao Shi et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Design and Evaluation of Potent EGFR Inhibitors through the Incorporation of Macrocyclic Polyamine Moieties into the 4-Anilinoquinazoline Scaffold
Yilan Ju et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Design, synthesis and characterization of novel quinacrine analogs that preferentially kill cancer over non-cancer cells through the down-regulation of Bcl-2 and up-regulation of Bax and Bad
V. Raja Solomon et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
Synthesis and biological evaluation of novel 6,11-dihydro-5H-benzo[e] pyrimido- [5,4-b][1,4]diazepine derivatives as potential c-Met inhibitors
Daowei Huang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
Discovery of novel anti-angiogenesis agents. Part 8: Diaryl thiourea bearing 1H-indazole-3-amine as multi-target RTKs inhibitors
Ying Sun et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
Design and synthesis of sulfonamide-substituted diphenylpyrimidines (SFA-DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors with improved activity toward B-cell lymphoblastic leukemia
He Liu et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
Design, synthesis and evaluation of azaacridine derivatives as dual-target EGFR and Src kinase inhibitors for antitumor treatment
Zhishan Cui et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
Discovery of potential anticancer multi-targeted ligustrazine based cyclohexanone and oxime analogs overcoming the cancer multidrug resistance
Gao-Feng Zha et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
Discovery of Potent, Selective Stem Cell Factor Receptor/Platelet Derived Growth Factor Receptor Alpha (c-KIT/PDGFRα) Dual Inhibitor for the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors (GISTs)
Yanli Lu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Design, Synthesis, and Pharmacological Evaluation of Novel Multisubstituted Pyridin-3-amine Derivatives as Multitargeted Protein Kinase Inhibitors for the Treatment of Non-Small Cell Lung Cancer
Wei Zhu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Structure-Guided Development of Covalent and Mutant-Selective Pyrazolopyrimidines to Target T790M Drug Resistance in Epidermal Growth Factor Receptor
Julian Engel et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
The target landscape of clinical kinase drugs
Susan Klaeger et al.
SCIENCE (2017)
Progress towards a public chemogenomic set for protein kinases and a call for contributions
David H. Drewry et al.
PLOS ONE (2017)
AXL Inhibitors in Cancer: A Medicinal Chemistry Perspective
Samuel H. Myers et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Comprehensive characterization of the Published Kinase Inhibitor Set
Jonathan M. Elkins et al.
NATURE BIOTECHNOLOGY (2016)
Delivery strategies and potential targets for siRNA in major cancer types
So Jin Lee et al.
ADVANCED DRUG DELIVERY REVIEWS (2016)
4-Anilinoquinazoline Derivatives with Epidermal Growth Factor Receptor Inhibitor Activity
Fang Liu et al.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2016)
Expanding the structural diversity of diarylureas as multi-target tyrosine kinase inhibitors
Yuanyuan Shan et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2016)
Rational Design, Synthesis, and Biological Evaluation of 7-Azaindole Derivatives as Potent Focused Multi-Targeted Kinase Inhibitors
Benedicte Dayde-Cazals et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
From Lead to Drug Candidate: Optimization of 3-(Phenylethyny1)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as Agents for the Treatment of Triple Negative Breast Cancer
Chun-Hui Zhang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
EGFR inhibitors identified as a potential treatment for chordoma in a focused compound screen
Susanne Scheipl et al.
JOURNAL OF PATHOLOGY (2016)
E7090, a Novel Selective Inhibitor of Fibroblast Growth Factor Receptors, Displays Potent Antitumor Activity and Prolongs Survival in Preclinical Models
Saori Watanabe Miyano et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Discovery of Novel Bruton's Tyrosine Kinase (BTK) Inhibitors Bearing a N,9-Diphenyl-9H-purin-2-amine Scaffold
Yang Ge et al.
ACS MEDICINAL CHEMISTRY LETTERS (2016)
DCLAK11, a multi-tyrosine kinase inhibitor, exhibits potent antitumor and antiangiogenic activity in vitro
Xiao-bin Guo et al.
ACTA PHARMACOLOGICA SINICA (2015)
Activation of transmembrane cell-surface receptors via a common mechanism? The rotation model''
Ichiro N. Maruyama
BIOESSAYS (2015)
The design, synthesis and biological evaluation of conformationally restricted 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as multi-targeted receptor tyrosine kinase and microtubule inhibitors as potential antitumor agents
Xin Zhang et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2015)
Genome-Wide Identification and Characterization of Novel Factors Conferring Resistance to Topoisomerase II Poisons in Cancer
Ruud H. Wijdeven et al.
CANCER RESEARCH (2015)
Discovery of 3,3a,4,5-tetrahydro-2H-benzo[g]indazole containing quinoxaline derivatives as novel EGFR/HER-2 dual inhibitors
Xi Zong et al.
RSC ADVANCES (2015)
The design and discovery of water soluble 4-substituted-2, 6-dimethylfuro[2,3-d]pyrimidines as multitargeted receptor tyrosine kinase inhibitors and microtubule targeting antitumor agents
Xin Zhang et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2014)
Synthesis and biological evaluation of novel pazopanib derivatives as antitumor agents
Haofei Qi et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2014)
Synthesis and biological evaluation of novel tricyclic oxazine and oxazepine fused quinazolines. Part 1: Erlotinib analogs
Xiangfeng Chen et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2014)
Design, synthesis and pharmacological evaluation of 6,7-disubstituted-4-phenoxyquinoline derivatives as potential antitumor agents
Shunguang Zhou et al.
BIOORGANIC CHEMISTRY (2014)
Non-receptor protein tyrosine kinases signaling pathways in normal and cancer cells
Elzbieta Gocek et al.
CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES (2014)
Novel 2-chloro-4-anilino-quinazoline derivatives as EGFR and VEGFR-2 dual inhibitors
Maria Leticia de Castro Barbosa et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2014)
Novel metal complexes of naphthalimide-cyclam conjugates as potential multi-target receptor tyrosine kinase (RTK) inhibitors: Synthesis and biological evaluation
Shaoying Tan et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2014)
Inhibition of tumor cell growth and angiogenesis by 7-Aminoalkoxy-4-aryloxy-quinazoline ureas, a novel series of multi-tyrosine kinase inhibitors
Severine Ravez et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2014)
Structure-Based Optimization of Tyrosine Kinase Inhibitor CLM3. Design, Synthesis, Functional Evaluation, and Molecular Modeling Studies
Stefania Sartini et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Clinical Targeting of Mutated and Wild-Type Protein Tyrosine Kinases in Cancer
Justin M. Drake et al.
MOLECULAR AND CELLULAR BIOLOGY (2014)
Kinase Drug Discovery - What's Next in the Field?
Philip Cohen et al.
ACS CHEMICAL BIOLOGY (2013)
Discovery of N-[5-({2-[(cyclopropylcarbonyl)amino]imidazo[1,2-b]pyridazin-6-yl}oxy)-2-methylphenyl]-1,3-dimethyl-1H-pyrazole-5-carboxamide (TAK-593), a highly potent VEGFR2 kinase inhibitor
Naoki Miyamoto et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2013)
Design, synthesis, and biological evaluation of novel 3-pyrrolo[b]cyclohexylene-2-dihydroindolinone derivatives as potent receptor tyrosine kinase inhibitors
Lei Ding et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2013)
Mechanism of Action of Conventional and Targeted Anticancer Therapies: Reinstating Immunosurveillance
Laurence Zitvogel et al.
IMMUNITY (2013)
Structure-Activity Relationship Studies of Pyrazolo[3,4-d]pyrimidine Derivatives Leading to the Discovery of a Novel Multikinase Inhibitor That Potently Inhibits FLT3 and VEGFR2 and Evaluation of Its Activity against Acute Myeloid Leukemia in Vitro and in Vivo
Ling-Ling Yang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells
Yanfang Fu et al.
NATURE BIOTECHNOLOGY (2013)
A public-private partnership to unlock the untargeted kinome
Stefan Knapp et al.
NATURE CHEMICAL BIOLOGY (2013)
Combination of siRNA-directed Gene Silencing With Cisplatin Reverses Drug Resistance in Human Non-small Cell Lung Cancer
Shanthi Ganesh et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2013)
Tyrosine kinase gene rearrangements in epithelial malignancies
Alice T. Shaw et al.
NATURE REVIEWS CANCER (2013)
Design, synthesis, and evaluation of imidazo[1,2-b]pyridazine derivatives having a benzamide unit as novel VEGFR2 kinase inhibitors
Naoki Miyamoto et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2012)
Discovery of AZD2932, a new Quinazoline Ether Inhibitor with high affinity for VEGFR-2 and PDGFR tyrosine kinases
Patrick A. Ple et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2012)
The Capicua repressor - a general sensor of RTK signaling in development and disease
Gerardo Jimenez et al.
JOURNAL OF CELL SCIENCE (2012)
AL3810, a multi-tyrosine kinase inhibitor, exhibits potent anti-angiogenic and anti-tumour activity via targeting VEGFR, FGFR and PDGFR
Yuanfeng Zhou et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2012)
VX-322: A Novel Dual Receptor Tyrosine Kinase Inhibitor for the Treatment of Acute Myelogenous Leukemia
David K. Heidary et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Synthesis and Biological Evaluation of Pyrimidine-Based Dual Inhibitors of Human Epidermal Growth Factor Receptor 1 (HER-1) and HER-2 Tyrosine Kinases
Mi Young Cha et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Tyrosine phosphorylation of the BRI1 receptor kinase occurs via a post-translational modification and is activated by the juxtamembrane domain
Man-Ho Oh et al.
FRONTIERS IN PLANT SCIENCE (2012)
Receptor tyrosine kinases: from biology to pathology
Mouna Choura et al.
JOURNAL OF RECEPTORS AND SIGNAL TRANSDUCTION (2011)
Activated Phosphoinositide 3-Kinase/AKT Signaling Confers Resistance to Trastuzumab but not Lapatinib (vol 9, pg 1489, 2010)
N. A. O'Brien
MOLECULAR CANCER THERAPEUTICS (2011)
Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity
Theonie Anastassiadis et al.
NATURE BIOTECHNOLOGY (2011)
Multiple molecular mechanisms underlying trastuzumab and lapatinib resistance in JIMT-1 breast cancer cells
Katri Koninki et al.
CANCER LETTERS (2010)
The (un)targeted cancer kinome
Oleg Fedorov et al.
NATURE CHEMICAL BIOLOGY (2010)
Tyrosine-phosphorylation: thirty years and counting
Tony Hunter
CURRENT OPINION IN CELL BIOLOGY (2009)
Design, synthesis and in vitro antitumor activity of 4-aminoquinoline and 4-aminoquinazoline derivatives targeting EGFR tyrosine kinase
Khaled Abouzid et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2008)
Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity
Rakesh Kumar et al.
MOLECULAR CANCER THERAPEUTICS (2007)
A small molecule-kinase interaction map for clinical kinase inhibitors
MA Fabian et al.
NATURE BIOTECHNOLOGY (2005)
Many commonly used siRNAs risk off-target activity
O Snove et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2004)
The protein kinase complement of the human genome
G Manning et al.
SCIENCE (2002)
Share Paper
